Jubilant Life Sciences rose 4.04% to Rs 367.20 at 10:38 IST on BSE after the company received final approval from the US Food and Drug Administration for the launch of generic version of a drug for the treatment of epilepsy.
The company made the announcement after market hours on Friday, 3 June 2016.Meanwhile, the S&P BSE Sensex was down 5.69 points or 0.02% at 26,837.34
On BSE, so far 53,360 shares were traded in the counter as against average daily volume of 1.53 lakh shares in the past one quarter. The stock hit a high of Rs 374 and a low of Rs 366.25 so far during the day. The stock had hit a record high of Rs 455 on 7 December 2015. The stock had hit a 52-week low of Rs 163.35 on 29 June 2015. The stock had underperformed the market over the past one month till 3 June 2016, falling 9.42% compared with Sensex's 6.39% rise. The scrip had also underperformed the market in past one quarter, declining 4.71% as against Sensex's 9.09% rise.
The mid-cap company has equity capital of Rs 15.93 crore. Face value per share is Re 1.
The approval is for the generic version of Keppra Injection 500mg/5mL (100mg/mL) of UCB, which is used for the treatment of epilepsy.
As on 31 March 2016, Jubilant Life Sciences had a total of 739 filings for formulations, of which 517 have been approved in various regions globally. This includes 72 ANDAs (Abbreviated New Drug Application) filed in the US, of which 44 have been approved. It also includes 46 dossier filings in Europe.
Jubilant Life Sciences' consolidated net profit rose 65.4% to Rs 70.68 crore on 2.8% fall in net sales to Rs 1480.29 crore in Q4 March 2016 over Q4 March 2015.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of active pharmaceutical ingredients, solid dosage formulations, specialty pharmaceuticals and life science ingredients. It also provides services in contract manufacturing and drug discovery solutions.
Powered by Capital Market - Live News
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app